HLAVNÍ TÉMA Diagnostika a léčba infekční endokarditidy | 85 / Vnitř Lék. 2025;71(2):72-85 / VNITŘNÍ LÉKAŘSTVÍ www.casopisvnitrnilekarstvi.cz 12. Hoen B, Duval X, Durack DT. Prevention of Infective Endocarditis. In: Bennett JE, Dolin R, Blaser MJ (eds.). Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases, 9th ed. Elsevier, 2020:1141-1150. 13. Kaplan SL, Vallejo JG. Infective Endocarditis. In: Cherry JD, Harrison GJ, Kaplan SL, Steinbach WJ, Hotez PJ (eds.). Feigin and Cherry’s Textbook of Pediatric Infectious Diseases, 8th ed. Elsevier, 2019:256-270. 14. Jindrák V, Hedlová D, Urbášková P, et al. Přístupy v používání antibiotik v klinické praxi. Antibiotická politika a prevence infekcí v nemocnici. Mladá fronta a. s.: Praha 2014. ISBN 978-80-204-2815-8. 15. Holland TL, Baddour LM, Bayer AS, Hoen B, Miro JM, Fowler VG Jr. Infective endocarditis. Nat Rev Dis Primers. 2016 Sep 1;2:16059. doi: 10.1038/nrdp.2016. 59. 16. Linhartová K, Beneš J, Gregor P. ESC Guidelines for the management of infective endocarditis. Summary document prepared by the Czech Society of Cardiology, Cor et Vasa. 2016;58:e107-e128. 17. Falcone M, Russo A, Cassetta MI, et al. Variability of pharmacokinetic parametres in patients receiving different dosages of daptomycin: is therapeutic drug monitoring necessary? J. Infect. Chemother. 2013;19:732-739. 18. Galar A, Munoz P, Valerio M, et al. Current use of daptomycin and systematic therapeutic drug monitoring: clinical experience in a tertiary care insitution. Int. J. Antimicro. Agents. 2019;53:40-48. 19. Garreau R, Pham TT, Bourguignon L, et al. Daptomycin Exposure as a Risk Factor for Daptomycin-Induced Eosinophilic Pneumonia and Muscular Toxicity. Clin Infect Dis. 2023 Nov 17;77(10):1372-1380. doi: 10.1093/cid/ciad386. 20. SPC. Cubicin, Cubicin, Summary of Produc Characteristics:https://prehledy.sukl.cz/ prehled_leciv.html#. 21. Crass RL, Powell KL, Huang AM. Daptomycin for the treatment of Staphylococcus aureus infections complicated by septic pulmonary emboli. Diagn Microbiol Infect Dis. 2019 Feb;93(2):131-135. doi: 10.1016/j.diagmicrobio.2018. 09. 004 22. Zainah H, Zervos M, Stephane W, Chamas Alhelo S, Alkhoury G, Weinmann A. Daptomycin Failure for Treatment of Pulmonary Septic Emboli in Native Tricuspid and Mitral Valve Methicillin-Resistant Staphylococcus aureus Endocarditis. Case Rep Infect Dis. 2013;653582. doi: 10.1155/2013/653582. 23. Wallenburg E, Ter Heine R, de Lange DW, et al. High unbound flucloxacillin fraction in critically ill patients. J Antimicrob Chemother. 2021 Nov 12;76(12):3220-3228. doi: 10.1093/jac/dkab314. 24. Kubíčková V, Vojtová V, Urbánek K. Farmakokinetické vlastnosti flukloxacilinu. Klinická farmakologie a farmacie. 2023;37(1):34-38. 25. Rybak MJ, Lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists [published correction appears in Am J Health Syst Pharm. 2009;66(10):887]. Am J Health Syst Pharm. 2009;66(1):82-98. Available from https:// www.ncbi.nlm.nih.gov/pubmed/19106348 26. Hanberger H, Edlund C, Furebring M, et al. Rational use of aminoglycosides — review and recommendations by the Swedish Reference Group for Antibiotics (SRGA). Scandinavian journal of infectious diseases. 2013 Mar 1;45(3):161-75. 27. Jackson J, Chen C, Buising K. Aminoglycosides: how should we use them in the 21st century? Current opinion in infectious diseases. 2013 Dec 1;26(6):516-25. 28. Hong LT, Downes KJ, Fakhri Ravari A, et al. International consensus recommendations for the use of prolonged-infusion beta-lactam antibiotics: Endorsed by the American College of Clinical Pharmacy, British Society for Antimicrobial Chemotherapy, Cystic Fibrosis Foundation, European Society of Clinical Microbiology and Infectious Diseases, Infectious Diseases Society of America, Society of Critical Care Medicine, and Society of Infectious Diseases Pharmacists. Pharmacotherapy. 2023 Aug;43(8):740777. doi: 10.1002/phar.2842 MÍSTO KONÁNÍ: Teoretické ústavy LF UP Olomouc, areál Fakultní nemocnice TEMATICKÉ OKRUHY: VNITŘNÍ LÉKAŘSTVÍ VČETNĚ DÍLČÍCH A NAVAZUJÍCÍCH OBORŮ Více informací a možnost přihlášení on-line na www.dnymladychinternistu.cz Registrace: on-line v registračním formuláři na www.dnymladychinternistu.cz e-mailem na registrace@solen.cz Účastnický poplatek: 1 500 Kč 5.–6. 6. 2025 / OLOMOUC 42. dny mladých internistů
RkJQdWJsaXNoZXIy NDA4Mjc=